Physician profile
Vivek Mehta
NPI 1568438760
$15,388.14
in general payments reported to CMS, 2019-2025
39 companies · $5,123 in 2025
The $5,123 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,904 · 2020: $180 · 2021: $526 · 2022: $981 · 2023: $2,308 · 2024: $2,366 · 2025: $5,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,779 · Travel and Lodging: $1,936 · Education: $81.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,778.52 |
| Travel and Lodging | $1,935.99 |
| Education | $81.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,640.82 | 2019-2025 | |
| Allergan, INC. | $2,838.95 | 2019 | |
| Medtronic, INC. | $2,753.94 | 2021-2025 | Stealthstation S8 Platform, Gi Genius, Endoflip |
| Janssen Biotech, INC. | $1,266.17 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $738.40 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.44 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Madrigal Pharmaceuticals | $403.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $335.00 | 2021-2023 | |
| Conmed Corporation | $306.07 | 2023-2025 | Conmed Biliary, Conmed Generators |
| Ipsen Biopharmaceuticals, INC | $255.33 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $221.16 | 2019-2025 | |
| Pfizer INC. | $196.46 | 2019-2025 | |
| Evoke Pharma, INC. | $183.73 | 2022-2024 | Gimoti |
| Celgene Corporation | $183.12 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $176.11 | 2024-2025 | Zenpep |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $155.31 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $151.28 | 2025 | Wegovy |
| Lilly USA, LLC | $138.48 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $115.98 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.62 | 2023-2024 | Cyltezo |
| Ferring Pharmaceuticals INC. | $106.87 | 2022-2025 | Rebyota |
| Qol Medical, LLC | $91.90 | 2022-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $65.59 | 2019-2024 | |
| Braintree Laboratories, INC. | $56.68 | 2020-2024 | Suflave, Sutab |
| Vivus LLC | $52.09 | 2024-2025 | Pancreaze |
| Celltrion USA INC. | $49.04 | 2024 | Zymfentra, Vegzelma |
| Ucb, INC. | $42.78 | 2019 | |
| Cook Medical LLC | $41.41 | 2023 | Fusion |
| Mallinckrodt Hospital Products INC. | $35.45 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $32.44 | 2023 | Dificid |
| Genzyme Corporation | $26.14 | 2025 | |
| Mirum Pharmaceuticals, INC. | $24.95 | 2025 | Livmarli |
| Daiichi Sankyo INC. | $24.87 | 2020-2022 | |
| Abbott Laboratories | $20.21 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Romark Laboratories, Lc | $15.91 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.20 | 2025 | Voquezna |
| Exact Sciences Corporation | $14.81 | 2023 | Cologuard Collection Kit |
| Phadia US INC. | $13.63 | 2022 | |
| Shire North American Group INC | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.